EFFICACY OF CETUXIMAB/PANITUMUMAB AFTER PREVIOUS BEVACIZUMAB IN METASTATIC COLORECTAL CANCER

被引：6

作者：

Gherman, Alexandra ^{[1
]}

Cainap, Calin ^{[1
,2
]}

Vesa, Stefan-Cristian ^{[3
]}

Havasi, Andrei Dan ^{[2
]}

Trifon, Alexandra ^{[4
]}

Cainap, Simona Sorana ^{[5
,6
]}

Crisan, Ovidiu ^{[7
]}

Irimie, Alexandru ^{[8
,9
]}

机构：

[1] Iuliu Hatieganu Univ Med & Pharm, Dept Med Oncol 11, Cluj Napoca, Romania

[2] Oncol Inst Prof Dr Ion Chiricuta, Dept Med Oncol, Cluj Napoca, Romania

[3] Iuliu Hatieganu Univ Med & Pharm, Dept Pharmacol Toxicol & Clin Pharmacol, Cluj Napoca, Romania

[4] Reg Inst Gastroenterol & Hepatol Prof Dr O Fodor, Cluj Napoca, Romania

[5] Emergency Cty Hosp Children, Pediat Clin 2, Dept Paediat Cardiol, Cluj Napoca, Romania

[6] Iuliu Hatieganu Univ Med & Pharm, Dept Mother & Child, Cluj Napoca, Romania

[7] Iuliu Hatieganu Univ Med & Pharm, Dept Organ Chem, Cluj Napoca, Romania

[8] Iuliu Hatieganu Univ Med & Pharm, Dept Oncol Surg & Gynaecol Oncol 11, Cluj Napoca, Romania

[9] Oncol Inst Prof Dr Ion Chiricuta, Dept Surg, Cluj Napoca, Romania

来源：

FARMACIA | 2020年 / 68卷 / 04期

关键词：

colorectal cancer; EGFR inhibitors; sequence; bevacizumab; FOLFIRI PLUS CETUXIMAB; ANTI-EGFR THERAPY; COLON-CANCER; CHEMOTHERAPY; SURVIVAL; GROWTH; KRAS; RESISTANCE; PROGNOSIS; IMPACT;

D O I：

10.31925/farmacia.2020.4.10

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The optimal sequence of the targeted therapies in metastatic colorectal cancer is not established. We aimed to analyse if previous administration of bevacizumab impacts the response to epidermal growth factor receptor inhibitors in subsequent lines of therapy. It was performed a retrospective analysis on KRAS or KRAS/NRAS wild-type metastatic colorectal cancer patients that received an epidermal growth factor receptor inhibitor in the second or later lines of therapy and their outcomes were analysed according to previous exposure to bevacizumab. 85 metastatic colorectal cancer patients were included, of whom 22 had received previous chemotherapy (group A) and 63 previous chemotherapy plus bevacizumab (group B). The overall survival was significantly higher in the group B (35.6 months versus 24.8 months, p = 0.01). The overall survival and progression-free survival calculated from the start of the epidermal growth factor receptor inhibitor did not significantly differ between the groups. The multivariate analysis revealed that using bevacizumab did not significantly impact the survival. Our results show that previous administration of bevacizumab does not influence the efficacy of epidermal growth factor receptor inhibitors in later lines of treatment.

引用

页码：656 / 664

页数：9

共 29 条

[1] Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry [J].

Burge, Matthew ;

Semira, Christine ;

Lee, Belinda ;

Lee, Margaret ;

Kosmider, Suzanne ;

Wong, Rachel ;

Shapiro, Jeremy ;

Ma, Brigette ;

Dean, Andrew P. ;

Zimet, Allan S. ;

Steel, Simone A. ;

Lok, Sheau Wen ;

Torres, Javier ;

Eastgate, Melissa ;

Wong, Hui-li ;

Gibbs, Peter .

CLINICAL COLORECTAL CANCER, 2018, 17 (03) :E593-E599

[2]

Cainap SS, 2016, FARMACIA, V64, P487

[3]

Ciardiello F, 2000, CLIN CANCER RES, V6, P3739

[4] POSSIBLE MOLECULAR MECHANISMS AND PATHWAYS INVOLVED IN BH3 MIMETIC ACTIVITY OF ALPHA-LIPOIC ACID ON HUMAN COLON CANCER CELL LINE [J].

Damnjanovic, Ivana ;

Kocic, Gordana ;

Najman, Stevo ;

Stojanovic, Sanja ;

Tomovic, Katarina ;

Ilic, Budimir ;

Veljkovic, Andrej ;

Pesic, Srdjan ;

Smelcerovic, Andrija .

FARMACIA, 2019, 67 (02) :226-234

[5] Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? [J].

Derangere, Valentin ;

Fumet, Jean David ;

Boidot, Romain ;

Bengrine, Leila ;

Limagne, Emeric ;

Chevriaux, Angelique ;

Vincent, Julie ;

Ladoire, Sylvain ;

Apetoh, Lionel ;

Rebe, Cedric ;

Ghiringhelli, Francois .

ONCOTARGET, 2016, 7 (08) :9310-9322

[6] Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database [J].

Franko, Jan ;

Shi, Qian ;

Meyers, Jeffrey P. ;

Maughan, Timothy S. ;

Adams, Richard A. ;

Seymour, Matthew T. ;

Saltz, Leonard ;

Punt, Cornelis J. A. ;

Koopman, Miriam ;

Tournigand, Christophe ;

Tebbutt, Niall C. ;

Diaz-Rubio, Eduardo ;

Souglakos, John ;

Falcone, Alfredo ;

Chibaudel, Benoist ;

Heinemann, Volker ;

Moen, Joseph ;

De Gramont, Aimery ;

Sargent, Daniel J. ;

Grothey, Axel .

LANCET ONCOLOGY, 2016, 17 (12) :1709-1719

[7]

Gheorghe-Cetean S, 2017, J BUON, V22, P568

[8] Surgical Resection of the Primary Tumor in Stage IV Colorectal Cancer Without Metastasectomy Is Associated With Improved Overall Survival Compared With Chemotherapy/Radiation Therapy Alone [J].

Gulack, Brian C. ;

Nussbaum, Daniel P. ;

Keenan, Jeffrey E. ;

Ganapathi, Asvin M. ;

Sun, Zhifei ;

Worni, Mathias ;

Migaly, John ;

Mantyh, Christopher R. .

DISEASES OF THE COLON & RECTUM, 2016, 59 (04) :299-305

[9] A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer [J].

Hecht, J. Randolph ;

Mitchell, Edith ;

Chidiac, Tarek ;

Scroggin, Carroll ;

Hagenstad, Christopher ;

Spigel, David ;

Marshall, John ;

Cohn, Allen ;

McCollum, David ;

Stella, Philip ;

Deeter, Robert ;

Shahin, Seta ;

Amado, Rafael G. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :672-680

[10] Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer [J].

Hsu, Hung-Chih ;

Liu, Yu-Chun ;

Wang, Chuang-Wei ;

Chou, Wen-Chi ;

Hsu, Yu-Jen ;

Chiang, Jy-Ming ;

Lin, Yung-Chang ;

Yang, Tsai-Sheng .

CANCER MEDICINE, 2019, 8 (07) :3437-3446

← 1 2 3 →